Gold Nanoparticles Conjugated L- lysine for Improving Cisplatin Delivery to Human Breast Cancer Cells

(E-pub Ahead of Print)

Author(s): Mahdieh Ganji, Fariba Dashtestani*, Hoda Keshmiri Neghab, Mohammad Hasan Soheilifar, Fatemeh Hakimian, Fatemeh Haghiralsadat

Journal Name: Current Drug Delivery

Become EABM
Become Reviewer
Call for Editor


An anticancer drug, cisplatin (CDDP) conjugated gold nanoparticles (GNPs) via L-Lysine (Lys) linker exhibiting a significant toxicity against cancer cells. The produced nanodrug (GNPs-Lys-CDDP) was charachterized by UV-Vis spectroscopy, dynamic light scattering (DLS), Zeta potentials and electron force microscopy. The cytotoxic efficacy of the GNPs-Lys-CDDP against human breast cancer cells (SKBR3) and normal cells (MCF-10A) was evaluatedby MTT assay. Cell apoptosis and morphology changes were assessed by flowcytometery and acridine orange/ethidium bromide (AO/EtBr) staining, respectively. It was found that the GNPs-Lys-CDDP with a size of 85 nm and negatively charged with a zeta-potential of about −25 mV could be taken up by tumor cells. A marked change in the UV spectrum of GNPs-LysCDDP compare to GNPs showed a strong absorption shift in the 525 nm region. The LD50 of GNPs-Lys-CDDP against SKBR3 (1 µ, was found to be 8 times lower than that of naked CDDP against SKBR3 (8 µ The nanocomplex GNPs-Lys-CDDP also significantly increased the apoptosis of SKBR3 with the lowest cytotoxic effects on normal cells. This work indicates that GNPs effectively could decrease the lethal dose of CDDP to 87%. Hence, GNPs modified by Lys, could be a good nano-carrier for chemotherapeutic drugs.

Keywords: Drug delivery, gold nanoparticles, cancer treatment drug, L-lysine, cisplatin, DLS.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1567201818666201203150931
Price: $95

Article Metrics

PDF: 2